# Undecimal Bio raises €16 million for targeted RNA delivery

_Published Tuesday, October 13, 2026 at 8:30 AM EDT · Capital · Latest · Tier 2 — Notable_

Cambridge-based Undecimal Bio announced €16 million ($18 million) in seed financing to expand its platform for delivering RNA medicines to specific cell types. 4BIO Capital and IQ Capital co-led the round, which will also support renovascular disease programmes and hiring at its Cambridge laboratories.

The company says its DELiveri platform screens chemical libraries and uses AI to identify molecules that can carry siRNA into target cells. Reaching tissues beyond the liver remains a key obstacle for these medicines; the funding supports delivery development rather than an established treatment.

## Sources

- [EU-Startups](https://www.eu-startups.com/2026/10/undecimal-bio-lands-e16-million-to-develop-targeted-rna-medicines-beyond-the-liver/)

---
Canonical: https://techandbusiness.org/newswire/PMumRoDZsforUZvFxwizTM
Published: 2026-10-13T12:30:25.557Z
Story chronology: 2026-10-13T11:42:51.000Z
Retrieved: 2026-10-13T14:48:57.255Z
Publisher: Tech & Business (techandbusiness.org)